Podcasts about phdprofessor

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO's independent conference coverage of CROI 2025, including:Advances in HIV treatment based on results from CARESPotential HIV therapies in the pipeline, such as doravirine/islatravirEffects of broadly neutralizing antibodies on HIV treatment and cure Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMPPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationHonorary Consultant Physician, Barts Health NHS TrustFaculty of Medicine and DentistryQueen Mary University of LondonLondon, United KingdomJean-Michel Molina, MD, PhDProfessor of MedicineUniversity of Paris CiteDepartment of Infectious DiseasesSaint-Louis and Lariboisiere Hospitals, APHPParis, FranceLink to full program:bit.ly/3E1bAYQTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.Launch Date: January 9, 2025Release Date: January 9, 2025Expiration Date: December 31, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this episode, Jean-Michel Molina, MD, PhD, and Joseph J. Eron, Jr., MD, discuss results from key clinical trials on HIV prevention and treatment as well as sexually transmitted infection (STI) prevention presented at IDWeek and Glasgow 2024, including:PURPOSE 1 and 2 comparing lenacapavir injection vs oral TDF/FTCTRIO Health Cohort and OPERA examining long-acting cabotegravir as PrEPDOLCE comparing DTG/3TC as first-line therapy in treatment-naive patients with HIVPRIDOX evaluating the use of DoxyPEP on STI incidence in men who have sex with men on PrEPPresenters:Jean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and lariboisièreParis, FranceJoseph J. Eron, Jr., MDProfessor of Medicine, School of MedicineHerman and Louise Smith Distinguished ProfessorChief, Division of Infectious DiseasesDirector, Clinical Core, UNC Center for AIDS ResearchAdjunct Professor of Epidemiology, Gillings School of Global Public HealthUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program: https://bit.ly/3BBaZvJ

This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussion highlights the pathophysiology of HLH as an interferon gamma (IFN-γ) driven disease, emphasizing the role of novel diagnostic tools such as flow cytometry and genetic panels. The panel also examines emerging therapies, including JAK inhibitors and IFN-γ monoclonal antibody (emapalumab), in improving outcomes for both primary and secondary HLH. Practical insights into balancing immunosuppression with efficacy offer guidance for optimizing patient care.Launch Date: December 2, 2024Release Date: December 2, 2024Expiration Date: November 30, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.Launch Date: November 25, 2024Release Date: November 25 2024Expiration Date: October 31, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Today, Vanessa got the opportunity to chat with Zak and Jenna about the very interesting and very factual childfree research they do! Jennifer Watling Neal, Ph.D.Professor, Psychology, Michigan State University  Co-Editor, Methodological Articles, Social DevelopmentFollow Jenna on IG @jennawneal Zachary Neal, PhDProfessor, Michigan State UniversityEditor, Evidence & PolicyEditor, Global Networkswww.zacharyneal.comNote: Todays episode is solely hosted by Vanessa, as Daliyce was still without power due to Hurricane Helene at the time of recording. Support the showEmail: claimingzeropodcast@gmail.comIG/FB: @claimingzero

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they'll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they'll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they'll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for CLL/SLL, including:Prognostic variables when deciding between regimensRole of MRD in CLLResults from the phase II CAPTIVATE trialChoosing among the available covalent BTK inhibitorsPreferred partner anti-CD20 antibody in CLL/SLLRole of the noncovalent BTK inhibitor, pirtobrutinib, in CLL/SLLUse of CAR T-cell therapy in CLL/SLLPresenters:Farrukh Awan, MDProfessor of Internal MedicineDirector of Lymphoid Malignancies ProgramHarold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallas, TexasJeremy S. Abramson, MD, MMScDirector, Center for LymphomaMassachusetts General HospitalAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsShuo Ma, MD, PhDProfessor of MedicineDivision of Hematology-OncologyDepartment of MedicineRobert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicago, IllinoisContent based on an online CME program supported by educational grants from BeiGene; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly, and an independent medical education grant from AbbVie.Link to full program:https://bit.ly/3LzA2As

Contents Podcast Panelists Additional Resources Transcript   In the fall of 2023, we kicked off our three-part Place Matters webinar series with our first installment: “A New Lens on Poverty: Working Towards Fairness of Place in the United States.” The webinar discussion featured the work of Mona Hanna-Attisha, MD, MPH, FAAP, whose research uncovered the water crisis in Flint, H. Luke Shaefer, PhD, co-author of the new book The Injustice of Place: Uncovering the Legacy of Poverty in America, and their groundbreaking new program, RxKids, an innovative effort to address child poverty and improve health equity. This conversation, moderated by our Chief Science Officer, Lindsey Burghardt, MD, MPH, FAAP, has been adapted for the Brain Architects podcast.   Panelists Mona Hanna-Attisha, MD, MPH, FAAPFounding Director, Pediatric Public Health Initiative  H. Luke Shaefer, PhDProfessor of Public Policy and Director of Policy Solutions, University of Michigan  Lindsey C. Burghardt, MD, MPH, FAAP (Moderator)Chief Science Officer, Center on the Developing Child at Harvard University Rebecca Hansen, MFA (Webinar Host)Director of Communications, Center on the Developing Child at Harvard University Amelia Johnson (Podcast Host)Communications Specialist, Center on the Developing Child at Harvard University Additional Resources Place Matters: The Environment We Create Shapes the Foundations of Healthy Development RxKids The Injustice of Place: Uncovering the Legacy of Poverty in America What the Eyes Don't See: A Story of Crisis, Resistance, and Hope in an American City Transcript Amelia Johnson: Welcome to The Brain Architects, a podcast from the Center on the Developing Child at Harvard University. I'm Amelia Johnson, the Center's Communications Specialist. Our Center believes that advances in the science of child development provide a powerful source of new ideas that can improve outcomes for children and their caregivers. By sharing the latest science from the field, we hope to help you make that science actionable and apply it in your work in ways that can increase your impact.  In October, we kicked off our three-part Place Matters webinar series with our first installment: “A New Lens on Poverty: Working Towards Fairness of Place in the United States.” During the webinar, Dr. Lindsey Burghardt, our Chief Science Officer, moderated a discussion between Dr. Mona Hanna-Attisha, whose research uncovered the water crisis in Flint, and H. Luke Shaefer, co-author of the new book The Injustice of Place: Uncovering the Legacy of Poverty in America. The resulting explores how the qualities of the places where people live are shaped by historic and current policies, which have created deep disadvantage across many communities with important implications for the health and development of the children who live there. We're happy to share these insights with you all on today's episode.  Now, without further ado, here's Rebecca Hansen, the Center's Director of Communications, who will set the stage with a brief overview of the webinar series.  Rebecca Hansen: Alright, hello, everyone. My name is Rebecca Hansen, and I'm the Director of Communications here at the Center on the Developing Child. And I'm very excited to welcome you all to today's webinar, A New Lens on Poverty: Working Toward Fairness of Place in the United States. This webinar is the first in an ongoing series designed to examine the many ways that a child's broader environment, including the built and natural environments, as well as the systemic factors that shape those environments, all play a role in shaping early childhood development beginning before birth. In this series, we will explore various environment tool influences from both scientific and community-based perspectives, including strategies to work toward fairness of place and improve existing conditions to allow all children to thrive.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:1. Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial Guest:Amy Clouse, MDAssociate DirectorFamily Medicine ResidencyJefferson Health – Abington.  2. Association Between Changes in Carbohydrate Intake and Long Term Weight Changes: Prospective Cohort StudyGuest:Walter C. Willett, MD, PhDProfessor of Epidemiology and NutritionHarvard T.H. Chan School of Public Health 3. Guidelines of care for the management of atopic dermatitis in adults with topical therapies – Journal of the American Academy of DermatologyGuest: Catherine McCormick, DO  Resident in the Family Medicine ResidencyJefferson Health – Abington.  Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. This Podcast Episode does not offer CME/CE Credit. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

In this episode, Brian Slomovitz, MD, MS, FACOG, and Keiichi Fujiwara, MD, PhD, share their thoughts and opinions on seminal data presented at the 2023 IGCS annual meeting for endometrial, ovarian, and cervical cancers, including:Phase III NRG GY018 trial of carboplatin and paclitaxel with or without pembrolizumab followed by pembrolizumab or placebo maintenance for 2 years in patients with measurable stage III/IVA, stage IVB, or recurrent endometrial cancer. Phase III ENGOT-EN6/GOG-3031/RUBY trial of carboplatin and paclitaxel with or without dostarlimab followed by dostarlimab or placebo maintenance for 3 years in patients with primary advanced or recurrent endometrial cancer. Results from the double-blind, randomized, placebo-controlled phase III AtTEnd trial of atezolizumab plus carboplatin/paclitaxel in advanced or recurrent endometrial cancer.Randomized, multicenter, double-blind, placebo-controlled phase III DUO-E study of carboplatin and paclitaxel vs durvalumab plus carboplatin and paclitaxel followed by durvalumab maintenance with or without olaparib as frontline treatment of newly diagnosed, advanced, endometrial cancer.An international, randomized, multicenter phase III trial evaluating short-course chemotherapy followed by chemoradiation vs chemoradiation alone in patients with newly diagnosed stage IB1N+, IB2, II, IIIB, IVA squamous, adeno, adenosquamous cervical cancer (INTERLACE).Randomized, double-blind, placebo-controlled phase III KEYNOTE-A18 trial of pembrolizumab plus concurrent chemoradiotherapy vs placebo plus chemoradiation in patients with high-risk locally advanced cervical cancer.Phase III ICON8B study comparing carboplatin, paclitaxel, and bevacizumab every 3 weeks vs dose-dense weekly paclitaxel plus bevacizumab every 3 weeks in newly diagnosed high-risk epithelial ovarian cancer, either stage III (with residual disease or requiring new adjuvant chemotherapy) or stage IV.Presenters:Brian Slomovitz, MD, MS, FACOGDirectorGynecologic OncologyMount Sinai Medical CenterProfessorObsterics and GynecologyFlorida International UniversityMember, Board of DirectorsGOG FoundationUterine Cancer LeadGOG PartnersMiami, Florida Keiichi Fujiwara, MD, PhDProfessor of Gynecologic OncologySaitama Medical University International Medical CenterHidaka, JapanProfessor of OBGYNInternational University of Health and WelfareNarita, JapanThis educational activity is supported by educational grants from AstraZeneca, Genmab, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, and Seagen. Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/424E3Uq

In this episode, Jean-Michel Molina, MD, PhD, discusses the data and recommendations for considering on-demand PrEP as a strategy to support PrEP persistence and engagement for men who have sex with men, including:Nondaily PrEP options recommended for cisgender menData from the ANRS IPERGAY study evaluating on-demand FTC/TDF vs placebo in men who have sex with menReal-world data on the effectiveness of on-demand PrEPConsiderations for on-demand FTC/TDF in people with renal dysfunctionData on hypertension and statin initiation risk with FTC/TAF PrEPData on weight gain with the different PrEP optionsFacultyJean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and LariboisièreParis, FranceFollow along with the slideshttps://bit.ly/47VGZVLLink to full program:https://bit.ly/3ZlICsL

FEATURED RESEARCHERAlex Leow, PhDProfessor of Psychiatry University of Illinois ChicagoOn X @alexfeuillet and LinkedInFEATURED PARTNERGregg F. Martin, PhDMajorGeneral, U.S. Army (Ret.)Author of Bipolar General: My Forever War with Mental IllnessOn X @GenGreggMartin & LinkedIn If you would like to see your interdisciplinary team featured on the podcast, reach out to me at laurenw@uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch. The University of Illinois Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

FEATURED RESEARCHERAlex Leow, PhDProfessor of Psychiatry University of Illinois ChicagoOn X @alexfeuillet and LinkedInFEATURED PARTNERGregg F. Martin, PhDMajorGeneral, U.S. Army (Ret.)Author of Bipolar General: My Forever War with Mental IllnessOn X @GenGreggMartin & LinkedIn If you would like to see your interdisciplinary team featured on the podcast, reach out to me at laurenw@uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch. The University of Illinois Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

In this episode, global PrEP experts and advocates discuss barriers that have prevented the full potential of today's PrEP regimens from being delivered, how those barriers might be overcome, and how the next generation of PrEP modalities may address unmet needs, including: How access and implementation of PrEP have limited its benefit and led to disparities in uptake among racial and ethnic groups in the United States and among key populations globallyThe challenges of adherence to PrEP for healthy individuals who are required to consistently take medication and engage with the healthcare system when they aren't sickThe potential for longer-acting PrEP modalities and a greater number of PrEP options for individuals in the future to expand PrEP uptake and adherence with equitable global accessFaculty: Jessica L. Adams, PharmD, AAHIVEScientific Director, Infectious DiseasesClinical Care OptionsNew York, United StatesLinda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV CentreUniversity of Cape TownSouth AfricaChief Executive OfficerThe Desmond Tutu Health FoundationCape Town, South AfricaKenyon R. FarrowPrEP AdvocateVice President of PolicyPoint Source YouthContributing EditorTheBody.comOhio, United StatesBeatriz Grinsztejn, MD, PhDDirectorSTI/AIDS Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilBrittany Williams, PhDPrEP AdvocateAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of Education University of Vermont Vermont, United StatesLink to full program: https://bit.ly/3FbPBey

In this episode, global PrEP experts and advocates discuss how current PrEP regimens represent a revolutionary step forward in enabling many individuals to avoid HIV acquisition, including: How PrEP has empowered people to take control of their sexual lives, revolutionized people's sexual experiences, and, for some, improved their experiences with healthcare in generalThe extraordinary progress that has been made in New South Wales and specifically in inner Sydney toward HIV transmission elimination and the role of PrEP in the prevention of new HIV infectionsThe importance of having PrEP options, including on-demand options and long-acting formulations, available to different populations who could benefit to see progress toward HIV transmission elimination globallyFaculty: Jessica L. Adams, PharmD, AAHIVEScientific Director, Infectious DiseasesClinical Care OptionsNew York, United StatesLinda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV CentreUniversity of Cape TownSouth AfricaChief Executive OfficerThe Desmond Tutu Health FoundationCape Town, South AfricaKenyon R. FarrowPrEP AdvocateVice President of PolicyPoint Source YouthContributing EditorTheBody.comOhio, United StatesBeatriz Grinsztejn, MD, PhDDirectorSTI/AIDS Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilAndrew Grulich, MBBS, PhDScientia ProfessorHead, HIV Epidemiology and Prevention ProgramThe Kirby InstituteUniversity of New South Wales, SydneyNew South Wales, AustraliaJean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and LariboisièreParis, FranceBrittany Williams, PhDPrEP AdvocateAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of Education University of Vermont Vermont, United StatesLink to full program: https://bit.ly/3FbPBey

In this first of 3 episodes, global HIV experts and advocates discuss how innovative models of care are minimizing barriers to HIV care engagement to improve uptake by key underserved populations, including:How peer support programs empower people to combat stigma, become more educated about treatment, and be engaged participants in their HIV careStrategies for addressing potential unmet mental healthcare needs among people living with HIVApproaches to reengage people with HIV who transit through county jail systemsHow integrated care strategies and wrap-around services can overcome some of the barriers to care that are associated with social determinants of healthKey considerations when providing HIV care for migrant and refugee populations Faculty:Ann Avery, MDProfessor of MedicineCase Western Reserve UniversityDivision of Infectious DiseasesMetroHealth Medical CenterCleveland, OhioJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesIsolde Butler, MD, MPHChief Medical OfficerCrescentCareNew Orleans, LouisianaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineDirector, Center for AIDS Research (CFAR)Medical Director, Ward 86 HIV ClinicUniversity of California, San Francisco (UCSF)San Francisco, CaliforniaMarissa GonzalezChairCommunity Advisory BoardThe Well ProjectAngelina NamibaFounder Member4M Network of Mentor MothersLondon, United KingdomChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesFaculty of Medicine and DentistryQueen Mary University of LondonBlizard InstituteBarts Health NHS TrustLondon, United KingdomMiłosz Parczewski, MD, PhDProfessor of MedicineDepartment HeadConsultant in Infectious DiseasesDepartment of Infectious, Tropical Diseases and Acquired ImmunodeficiencyPomeranian Medical UniversitySzczecin, PolandLink to full program:https://bit.ly/3QFwv7nLinks to programs discussed in the episode:https://4mmm.org/https://positivepeers.org/  

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, and Meredith Clement, MD, discuss PrEP initiation, including:The importance of taking a sexual history and getting to know your patientRecommendations for who should be considered for PrEPPracticalities of PrEP initiation including laboratory assessments, interview and physical exam, evaluating concomitant medications, counseling, and prescribingSummary of PrEP eligibility by regimenReview of the clinical trial and real-world data for each PrEP modalityThe likelihood of cross-resistance between PrEP options and ART options if someone were to become infected with HIV while receiving PrEPTime to effective concentrations of PrEP after initiationWhether there are data for on-demand dosing of FTC/TAFRecommendations for FTC/TDF on demand for heterosexual cisgender menIndividualizing PrEP for each person to increase the likelihood of adherence, persistence, and efficacyRecommendations for the use of LA CAB for PrEP during pregnancy and in people of childbearing potentialSTI and point-of-care testing for people receiving PrEPThe possibility of implantable PrEP in the futurePresenters:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV Centre University of Cape TownCape Town, South AfricaMeredith Clement, MD Assistant ProfessorSection of Infectious DiseasesLouisiana State University Health Sciences CenterUniversity Medical CenterNew Orleans, Louisiana Link to full program:https://bit.ly/3HPu4Lk

In this episode, Tarik Asselah, MD, PhD, and Ira Jacobson, MD, provide expert insight on HDV screening, diagnosis, and management, including:Approach to screeningBarriers to screening (eg, test availability)Disease progression and complicationsDifferentiating between coinfection and superinfectionApproach to treatment (eg, whom to treat and when, treatment options, considerations for combination therapy)Management of patients with decompensated cirrhosisSurrogate markers to measure treatment successRole of correcting thrombocytopenia before initiating therapyFaculty:Tarik Asselah, MD, PhDProfessor of Medicine Department of HepatologyHôpital BeaujonUniversité de ParisClichy, FranceIra Jacobson, MDProfessor of MedicineNYU School of MedicineDirector of HepatologyDivision of Gastroenterology and HepatologyNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3yp1Lxf 

Join Sarah for an exciting conversation with Dr. María Paz Moreno, PhD, who is a poet, literary critic, food writer and professor at the University of Cincinnati. Together, they explore the food we eat and its intersection with culture, community and health. Listen to the end for some recipe inspiration, and browse the show notes if you're hungry for more information!  María Paz's personal webpage: http://mariapazmoreno.com/ UC Research Directory page: https://researchdirectory.uc.edu/p/morenom My Amazon author page: https://www.amazon.com/stores/author/B00DX029DK?ingress=0&visitId=1d0f3ad2-608a-4ef1-bbf8-dc576fb26bc6&store_ref=ap_rdr&ref_=ap_rdr My book on the Culinary History of Madrid (in English): https://rowman.com/ISBN/9781442266414/Madrid-A-Culinary-History An Anthology of my poetry (English/Spanish), recently published in the US: http://valparaisoeditions.us/poetry/629-the-belly-of-an-iguana.html UC Honors Course on “Chocolate and Power”: https://www.uc.edu/campus-life/honors/students/experiences/seminars/seminar-spotlights/rall3080.html Contact: María Paz Moreno, PhDProfessor of SpanishDepartment of Romance and Arabic Languages & LiteraturesUniversity of CincinnatiCincinnati, Ohio 45221Phone: (513) 556-1834morenom@uc.eduhttps://researchdirectory.uc.edu/p/morenomPhoto credit: University of Cincinnati

In this episode, Suzanne Lentzsch, MD, Ph.D., and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of BCMA-targeted therapies in the management of patients with multiple myeloma, including their experiences and challenges with implementing recent data. This overview will include a discussion of: Considerations with administration, including access challengesSequencing TherapiesFuture developments with BCMA-targeted therapiesPresenters:Suzanne Lentzsch, MD, PhDProfessor of MedicineDivision of Hematology/OncologyDirector, Multiple Myeloma and Amyloidosis ProgramColumbia University Medical Center New York, New YorkJoseph Mikhael, MD, MEd, FRCPC, FACPProfessorApplied Cancer Research and Drug Discovery Translational Genomics Research Institute Phoenix, ArizonaChief Medical OfficerInternational Myeloma Foundation HonorHealth Research Institute Scottsdale, ArizonaProvided by Clinical Care Options, LLC in partnership with Smart Patients.Content supported by educational grants from AbbVie; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; and Regeneron Pharmaceuticals, Inc.Link to full program: bit.ly/41YEOO6 

Resources for Recovery:  Reading Ron Rash's Short Stories Alongside Formerly Incarcerated WomenMartha Greene Eads, PhDProfessor of EnglishEastern Mennonite University

Pathogens in Pop Culture: Fungal Pathogens and The Last of UsCould a fungus cause the next pandemic? If you've watched HBO's hit series ‘The Last of Us' or played the popular video game, then you may be familiar with the concept: a mass outbreak of an infectious fungus turns humans into zombies. But could the scenario played out in ‘The Last of Us' actually happen in real life? Join hosts Lauren Sauer and Rachel Lookadoo and special guest Dr. Arturo Casadevall as they take a closer look at the science behind fungal pathogens and separate myth from reality.Questions or comments for NETEC? Contact us at info@netec.org.Visit Transmission Interrupted on the web at netec.org/podcast.GuestArturo Casadevall, MD, PhDProfessor and Chair, Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health. Dr. Casadevall focuses on host defense mechanisms, how fungi cause disease, and in the development of antibody-based therapies for infectious diseases.Twitter: https://twitter.com/ACasadevall1HostsLauren Sauer, MScLauren is an Associate Professor in the College of Public Health, Department of Environmental, Agricultural, and Occupational Health, at the University of Nebraska Medical Center and Core Faculty of the UNMC Global Center for Health Security. She is an Adjunct Associate Professor of Emergency Medicine in the Johns Hopkins School of Medicine, and the director of the Special Pathogens Research Network.She previously served as Director of Operations for the Johns Hopkins Office of Critical Event Preparedness where she ran the inpatient COVID19 biobank and served on the COVID19 research steering committee for JHU. Lauren's research focuses on human subjects research in bio-emergencies and disasters, in particular, ethical implementation of research and navigating the regulatory environment. The goal of her research is to provide health care facilities with the tools needed to conduct a clinical and operational research response in emergencies.Rachel Lookadoo, JDRachel Lookadoo is an Assistant Professor in the Epidemiology department of the College of Public Health at the University of Nebraska Medical Center, and serves as the Deputy Director of the Center for Biosecurity, Biopreparedness, and Emerging Infectious Diseases. She also acts as the Director of Public Health Policy for the Water, Climate, and Health program at the University of Nebraska Medical Center. Ms. Lookadoo's background is as an attorney, and she focuses on the various legal and regulatory issues that can arise in emergency preparedness and response. She specializes in public health impacts of climate change, healthcare surge events, isolation/quarantine law, crisis standards of care, infectious disease response, and general legal preparedness. Ms. Lookadoo also conducts emergency preparedness trainings and assessments for public health departments and healthcare facilities nationally. Ms. Lookadoo received her Juris Doctor degree from American University Washington College of Law, and her Bachelor's degree from Baylor University.ResourcesCan a Fungus Cause a COVID-Style Pandemic? https://www.medpagetoday.com/popmedicine/popmedicine/103449?vrw=noWhy Fungal Diseases Are an Increasing Threat: https://magazine.jhsph.edu/2022/why-fungal-diseases-are-increasing-threat NETEC Resource Library: https://repository.netecweb.orgAbout NETECA...

In this episode, Daniel J. DeAngelo, MD, PhD; Kjeld Schmiegelow, MD, DMSci; and Emily Curran, MD, answer key questions asked by the audience during a live satellite symposium at the 2022 American Society of Hematology Annual Meeting on optimizing pediatric or pediatric-inspired regimens containing asparaginase for the treatment of young and older adults with acute lymphoblastic leukemia.Topics discussed include:Practical considerations for management of allergy-like reactions and hypersensitivity to asparaginaseIndirect methods for measuring asparaginase activityStrategies to mitigate adverse events with asparaginase treatment, including hepatotoxicity, pancreatitis, and thrombosisConsiderations for use of asparaginase in special populations (eg, high BMI, older age)Presenters:Program DirectorDaniel J. DeAngelo, MD, PhDProfessor of MedicineDepartment of MedicineHarvard Medical SchoolChief of the Division of LeukemiaDepartment of Medical OncologyDivision of Hematologic MalignanciesDana‐Farber Cancer InstituteBoston, MassachusettsEmily Curran, MDAssistant ProfessorDivision of Hematology/OncologyUniversity of Cincinnati Cancer InstituteCincinnati, OhioKjeld Schmiegelow, MD, DMSciProfessorDepartment of Pediatric OncologyRighospitalet University HospitalCopenhagen, DenmarkContent based on an online CME program supported by an independent educational grant from Jazz Pharmaceuticals.Link to full program:http://bit.ly/3YXkLyj 

Ryan Nixon, PhDProfessor, Teacher Education, Brigham Young University"Before you use Pinterest, think in advance about what it is you want your kids to learn and what you want them to be thinking about...If you don't have a decent idea of what your instructional goal is, there's a ton of stuff on Pinterest, and you can scroll and scroll and scroll and scroll. It's much more likely for you to be sucked into that if you don't really know what you're looking for, if you don't know what your goal is."

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer  • Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test  • Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial  • Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancerPresenters:Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, France  Ignace Vergote, MD, PhDProfessor Em. of Department of Obstetrics and Gynecologic OncologyUniversity Hospitals LeuvenLeuven, BelgiumContent supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries: https://bit.ly/3SSSqpN  

When it comes to managing older adults with hepatitis B virus (HBV), what comorbidity, comedication, and adherence issues should be considered?Listen as Graham R. Foster, FRCP, PhD, discusses these considerations and more for strategizing the monitoring and treatment of older adults with HBV. Presenter: Graham R. Foster, FRCP, PhDProfessor of HepatologyThe Liver UnitConsultant HepatologistQueen Mary University of LondonLondon, United KingdomLink to full program:https://bit.ly/3fg9fwB

Ellie Young, PhDProfessor, Counseling Psychology and Special Education, Brigham Young University "We may need to move beyond what we traditionally have done and look at how is this working. Could school counselors, school social workers, and school psychologists come together in different ways to support administrators and teachers?"

You can think of the “D” in HDV as standing for difficult, disadvantaged, and dangerous. Hepatitis delta virus (HDV) is difficult to diagnose, is often diagnosed in disadvantaged patient populations, and leads to dangerous sequelae.Listen as Dr. Kosh Agarwal and Dr. Graham R. Foster and discuss challenges and opportunities for linking patients to care after a positive test for HDV.Presenters:Kosh Agarwal, MDConsultant Hepatologist and Transplant PhysicianInstitute of Liver StudiesKing's College Hospital NHS Foundation TrustLondon, United KingdomGraham R. Foster, FRCP, PhDProfessor of HepatologyThe Liver UnitConsultant HepatologistQueen Mary University of LondonLondon, United KingdomLink to full program:https://bit.ly/3tlxa0H

FEATURED RESEARCHERSMarc Atkins, PhDProfessor of Psychiatry and Psychology Director, CCTS Community Engagement and Collaboration CoreGrace CuaSenior Research Specialist, CCTS Community Engaged Collaboration CoreGraduate Student, Educational psychology, UICFEATURED PARTNERJim PooleChief integration OfficerNAMI Chicago To learn more about burnout, you can read this 2016 article from World Psychiatry. If you would like to see your interdisciplinary team featured on the podcast, reach out to me at laurenw@uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch.The University of Illinois Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

> Listen anytime on Audacy.com.On Saturday, July 23, 2022, our host Dr. Marianne Ritchie was joined by Ronald Petersen, MD, PhD.Dr. Peterson is a Professor of Neurology and a world-class expert who has led the way in research on dementia, aging, and Alzheimer's Disease. He talked about some of the cognitive tests currently available and provided hopeful news about advances in the diagnosis and treatment of Alzheimer's Disease.Ronald Petersen, MD, PhDProfessor of Neurology, The Mayo ClinicCora Nakow Professor of Alzheimer's Disease ResearchDirector, Alzheimer's Disease Research CenterDirector, Mayo Clinic Study of AgingYour Real Champion® “The Patriotic Piper“Bob Waters is a Master of Bagpipe performance and has been rated as one of the top competitors in North America. A true patriot, nothing gives him more pride than to play for the men and women of the military service.Each year he brings hundreds of people together in Ocean City on July 4 as he plays patriotic music to mark the birth of our nation and show appreciation for our freedom.Each week we highlight the Real Champions in your life! Your family, friends, or colleagues who go the extra mile to help others in their community.Know someone who should be featured? →Nominate them now!Check out all of our past Champions →

Sarah Clark , PhDProfessor, Teacher Education, Brigham Young University"What I wish I could do is talk to them from their child's birth, instilling the desire to read and to engage with them. Not the skills, not to read a certain amount, but to read with wonder. To show or talk with them about books that you're reading, even though they're not at the level of the child. Get them to see you read."

In this episode,  Pietro Lampertico, MD, PhD, discusses what to do when treatment for hepatitis B virus (HBV) infection is not indicated, covering topics such as:The different phases of chronic HBV infectionWhich patients in different phases require immediate HBV treatment and which can be monitored without therapyThe critical importance of ongoing monitoring for patients who do not meet indications for immediate therapyThe tests and frequency that should be used for monitoring patients not receiving HBV treatmentPresenter:Pietro Lampertico, MD, PhDProfessor of GastroenterologyDirector, Division of Gastroenterology and HepatologyIRCCS Ca Granda Policlinico HospitalUniversity of MilanMilan, ItalyContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation. Link to full program: https://bit.ly/3OGHvOv

FEATURED RESEARCHERSClaire Decoteau, PhDProfessor, Department of SociologyCollege of Liberal Arts & SciencesUniversity of Illinois ChicagoIván ArenasAssociate DirectorInstitute for Research on Race and Public PolicyUniversity of Illinois at ChicagoLEARN MORE“Deadly Disparities in the time of COVID-19: How Public Policy Fails Black and Latinx Chicagoans,” December 2021View panel discussions from 12/01/2021 and 12/09/2021UIC Institute for Research on Race and Public Policy If you would like to see your interdisciplinary team featured on the podcast, reach out to me at laurenw@uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch.The University of Illinois Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 

A group of leading experts in pediatric neurology and movement disorders attended a virtual roundtable to discuss diagnostic, symptomatic, and research aspects of aromatic L-amino acid decarboxylase (AADC) deficiency.AADC deficiency is characterized by a defect in the dopa decarboxylase or DDC gene; this dysfunction leads to reduced production of the critical neurotransmitters dopamine, norepinephrine, epinephrine, and melatonin. As a result, patients with AADC deficiency can suffer deficits in vital motor function.The symptoms of this very rare genetic disorder usually appear before children reach one year of age. Patients with severe symptoms rarely survive beyond age 10. Although patients with moderate symptoms can live into adulthood, those afflicted with AADC deficiency often experience developmental disability and can require lifelong care. The participants included:Philip L. Pearl, MD Director, Epilepsy and Clinical Neurophysiology, Boston Children's HospitalWilliam G. Lennox Chair and Professor of Neurology, Harvard Medical SchoolBoston, MAWarren A. Marks, MDMedical Director, Movement DisordersCook Children's Jane and John Justin Neurosciences CenterFort Worth, TXPaul Wuh-Liang Hwu, MD, PhDProfessor, Department of Pediatrics and Medical GeneticsNational Taiwan University HospitalTapei, TaiwanIrina A. Anselm, MDDirector of the Mitochondrial Program and Co-Director of the Neurometabolic Program, Boston Children's HospitalAssistant Professor of Neurology, Harvard Medical SchoolBoston, MAJennifer O'Malley, MD, PhDClinical Assistant Professor, Neurology & Neurological Sciences, Stanford MedicinePediatric Neurologist, Stanford Children's HealthStanford, CAModerated by Dr. Pearl, the roundtable participants described the first recognized case of AADC deficiency, and the fact that the prevalence and incidence of the condition is not yet clear. One problem is that the presentation of infants with AADC deficiency is not very specific, and a large number of patients are probably not yet diagnosed, said Dr. O'Malley. Unexplained hypotonia is a useful sign, she explained, which clinicians can use to go down the path to diagnosis. Dr. Marks commented that when children present with movement disorders at his center, he has a very low threshold to begin genetic testing for AADC deficiency, which will rapidly eliminate or confirm the diagnosis. Dr. Hwu emphasized that clinical recognition is the first step: Once you make one diagnosis, it isn't too difficult to identify the second patient.Symptomatic treatment can be useful, particularly in patients with milder forms of AADC deficiency, said Dr. Anselm. For example, similar to Parkinsonism, dopamine agonists can have positive results, but dyskinesias are problematic.Gene therapy holds promise, according to Dr. Hwu, but he cautioned that even if successful, a good deal of movement training and patience will be required to gain movement control.Drs. O'Malley and Anselm believe that collaboration and education among the different disciplines (e.g., child neurologists and physiatrists) is key to improving recognition of AADC deficiency and gaining early treatment.

FEATURED RESEARCHERSNaoko Muramatsu, PhDProfessor, Community Health SciencesUIC School of Public HealthTwitter:  @naoko_muramatsuLinkedIn BioKelly Quinn, PhDClinical Associate ProfessorDepartment of CommunicationUIC College of Liberal Arts & ScienceTwitter: @_kquinn_ David Marquez, PhDProfessorDepartment of Kinesiology and NutritionUIC College of Applied Health SciencesTwitter: @DrDavidMarquezMarquez LabJessie Chin, PhDAssistant ProfessorSchool of Information SciencesUniversity of Illinois Urbana-ChampaignChin Lab If you would like to see your interdisciplinary team featured on the podcast, reach out to me at laurenw@uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch.The University of Illinois Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. 

In this episode, Robert G. Gish, MD, and Pietro Lampertico, MD, PhD, share lessons learned in the care of patients coinfected with hepatitis B virus and hepatitis delta virus (HDV), including:Burden of HDV infectionChronic HDV infection and comorbiditiesImpact of COVID-19 on care of patients with chronic hepatitis BScreening for HDV and which assays to useScreening for viral hepatitis at a COVID-19 vaccination sitePresenters:Robert G. Gish, MD, FAASLD, AGAF, FASTProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaClinical ProfessorUniversity of Nevada Reno School of MedicineReno, NevadaUniversity of California Skaggs School of Pharmacy and Pharmaceutical SciencesSan Diego, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCPietro Lampertico, MD, PhDProfessor of GastroenterologyDirector, Division of Gastroenterology and HepatologyIRCCS Ca Granda Policlinico HospitalUniversity of MilanMilan, ItalyFollow along with the slides at:https://bit.ly/3HQ6dZ5Link to full program: https://bit.ly/3Bgyd5I

In this episode, Ara Metjian, MD; Paul Coppo, MD, PhD; and Marshal Mazepa, MD, answer questions from an audience of healthcare professionals on topics related to the management of acquired thrombotic thrombocytopenic purpura (aTTP), including:  Rationale of the CAPLAVIE regimen of caplacizumab with corticosteroids and rituximab in aTTP in the acute phaseData for caplacizumab in pediatric patients with aTTPInitiating rituximab after completion of plasma exchangeInternational Society on Thrombosis and Haemostasis guideline recommendations against using aspirinTriggers of aTTP episodes aside from infectionEffect of COVID-19 vaccines and COVID-19 infections on aTTP onset or relapsePresenters:Ara Metjian, MDAssociate ProfessorDivision of HematologyDepartment of MedicineUniversity of Colorado, Anschutz Medical CampusAurora, ColoradoPaul Coppo, MD, PhDProfessor of HematologyHematology Department, AP-HPSorbonne UniversityParis, FranceMarshall Mazepa, MD Assistant Professor of MedicineDivision of Hematology, Oncology,  and TransplantationUniversity of MinnesotaMinneapolis, MinnesotaLink to the complete program, including downloadable slidesets, an expert commentary, an on-demand webcast, and healthcare professional resource guide:https://bit.ly/3J1fcad 

FEATURED RESEARCHERSAmy Lasek, PhDAssociate ProfessorDepartments of Psychiatry and Anatomy and Cell BiologyUniversity of Illinois at Chicago College of MedicineGregory Thatcher, PhDProfessor, Pharmacology and ToxicologyR. Ken and Donna Coit Endowed Chair in Drug DiscoveryR. Ken Coit College of Pharmacy, University of ArizonaManel Ben Aissa, PhDResearch Assistant Professor, Department of Pharmaceutical SciencesAssistant Director, UICentreUniversity of Illinois at Chicago College of Pharmacy To learn more about the UICentre, visit https://centre.pharmacy.uic.eduLearn more about the CCTS Pilot Grant program at ccts.uic.edu/funding If you would like to see your interdisciplinary team featured on the podcast, reach out to me at laurenw@uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch.The University of Illinois at Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.Presenters:Milena Murray, PharmD, MSc, BCIDP, AAHIVPAssociate Professor  Pharmacy PracticeMidwestern University College of Pharmacy, Downers Grove CampusDowners Grove, IllinoisHIV/ID Clinical PharmacistNorthwestern Memorial HospitalChicago, IllinoisJonah Musa, MBBS, MSCI, PhDProfessor, Obstetrics and GynecologyUniversity of JosHonorary Consultant Obstetrician and GynecologistJos University Teaching HospitalJos, NigeriaContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3GRxpGQLink to full program:https://bit.ly/2TXTYWx

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss the most important clinical trial data on leveraging TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.Presenters:Jean-Yves Blay, MD, PhDProfessor of Medical OncologyDepartment of MedicineCentre Leon BerardLyon, FranceRobin L. Jones, BSc, MBBS, MRCP, MD(Res)ProfessorSarcoma UnitRoyal Marsden Hospital and Institute of Cancer ResearchLondon, United KingdomLink to full program, including accompanying downloadable slidesets:https://bit.ly/2ZL9bxq

Timothy Smith, PhDProfessor, Counseling Psychology and Special Education, Brigham Young University"As much as we'd like to believe that it's all about doing what we can individually, we actually need to look at contexts and relationships. And where faith comes in, is the recognition that we are all interdependent. The very assertion that we can do it ourselves is actually against the notion of faith."

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapyA preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancerQuality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancerPresenters:Prof. Isabelle Ray-Coquard, MD, PhDProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, FranceBernard Doger de Spéville, MD, PhDMedical OncologistSTART-Madrid, Early Phase Clinical Trials UnitHospital Fundación Jiménez DíazMadrid, SpainContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:https://bit.ly/3dAttwi 

In this episode, Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, and Lewis R. Roberts, MB ChB, PhD, examine the HBV burden and care disparities in specific populations, including Asian Americans and foreign-born immigrants, and strategies to address barriers to care.Presenters:Mindie H. Nguyen, MD, MAS, AGAF, FAASLDProfessor of MedicineDepartment of Gastroenterology and HepatologyStanford University Medical CenterPalo Alto, CaliforniaLewis R. Roberts, MB ChB, PhDProfessor of Medicine and ConsultantDivision of Gastroenterology and HepatologyMayo ClinicRochester, MinnesotaContent based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP  To follow along, download the slides at: https://bit.ly/3gWStjZLink to full program:https://bit.ly/3kKIb9a 

Charles Graham, PhDProfessor, Instructional Psychology & Technology, Brigham Young University“The new normal is going to be a blended environment where teachers, and schools, and parents, have a toolbox that includes in-person learning options, as well as online learning options, and sometimes a mix of the two. . . .If teachers and parents are not trained, and don't have some understanding of how to make the online learning space effective, it's not going to be as effective.”

In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an  audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifenPresenters:Javier Cortes, MD, PhDHead, Breast Cancer ProgramIOB Institute of OncologyMadrid and Barcelona, SpainStephen R. D. Johnston, MA, FRCP, PhDProfessor of Breast Cancer MedicineBreast UnitDepartment of MedicineRoyal Marsden HospitalLondon, United KingdomSara Tolaney, MD, MPHAssistant Professor of MedicineHarvard Medical SchoolAssociate DirectorSusan F Smith Center for Women's CancerDirector of Clinical Trials, Breast Oncology  Director of Breast Immunotherapy  Clinical ResearchSenior PhysicianBreast Oncology ProgramDana-Farber Cancer InstituteBoston, Massachusetts, USAContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including downloadable slides and associated Podcast Pearls PDF:https://bit.ly/37tfvtj

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include:Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223Efficacy and toxicity of PSMA lutetium plus standard of care in the VISION trialOngoing trials evaluating radionuclides in combination with other agents in metastatic CRPCPresenters:Chris Parker, MDProfessor of Prostate OncologyInstitute of Cancer ResearchClinical OncologistDepartment of Uro-oncologyRoyal Marsden HospitalSutton, Surrey, United KingdomBertrand Tombal, MD, PhDProfessor of UrologyInstitut de Recherche Clinique (IRC)Cliniques universitaires Saint-LucChairmanDepartment of SurgeryCliniques universitaires Saint-LucBrussels, BelgiumLink to full program, including downloadable slides: https://bit.ly/36IEnNE

Featured researchers:Laura Sanchez, PhDAssociate Professor, Department of Biochemistry & ChemistryUniversity of California Santa CruzJoanna Burdette, PhDProfessor, Department of Pharmaceutical SciencesAssociate Dean for ResearchUniversity of Illinois at Chicago College of PharmacyLearn about funding and career development opportunities with the CCTS Pilot Grant Program and UIC BIRCWH Program .Interested in supporting cancer research at UIC? Visit the UI Cancer Center website . To learn more about translational research, visit ccts.uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch.The University of Illinois at Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Paul Caldarella, PhDProfessor, Counseling Psychology, Brigham Young University“Generally what we find is that the more often teachers praise, the better student behavior tends to be….We saw about a 20 to 30 percent improvement in student on-task behavior as praise rates increased.”

Featured researcher:Olusola Ajilore, MD, PhDAssociate Professor, Department of PsychiatryUniversity of Illinois at Chicago College of MedicineOther research team members mentioned:Alex Loew, MD, PhDAssociate Professor, Departments of Psychiatry and BioengineeringUniversity of Illinois Chicago College of MedicineJun Ma , MD, PhDProfessor of Academic Internal Medicine and Geriatrics, Department of MedicineUniversity of Illinois at Chicago College of MedicineTo learn more about translational research, visit ccts.uic.edu.Interested in volunteering to participate in health research? Today's researchers want to make sure that treatments and cures are designed for everyone's unique needs. Are you ready to make a difference? Learn more at go.uic.edu/healthresearch.The University of Illinois at Chicago Center for Clinical and Translational Science is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR002003. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.